Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05388838

Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis

Led by Hospices Civils de Lyon · Updated on 2025-03-03

60

Participants Needed

2

Research Sites

182 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis. Vitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible. The main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months. The INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO/2016/005548). A rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP. The research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP. The primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.

CONDITIONS

Official Title

Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female over 18 years of age
  • Signed free, informed, written consent before any study examination
  • Affiliated with a social security system or beneficiary
  • Sampling volume per 30-day period adapted to patient's weight
  • Patient with uveitis without ocular lymphoma and no cerebral lymphoma, or
  • Patient with primary ocular lymphoma without brain involvement, untreated or treated and in remission or relapse, or
  • Patient with cerebral lymphoma with or without ocular involvement but no uveitis, or
  • Patient with cataract, glaucoma, retinal detachment, epiretinal membrane but no brain damage or uveitis
Not Eligible

You will not qualify if you...

  • Participating in another clinical trial at inclusion
  • Pregnant, nursing mothers, or in labor
  • Deprived of liberty by judicial or administrative decision
  • Under psychiatric care
  • Admitted to health or social institution for non-research purposes
  • Under legal protection measures (guardianship, curatorship)
  • Diagnosis of ocular or cerebral lymphoma is uncertain
  • Have another systemic cancer evolving or in remission less than 2 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Service d'Ophtalmologie, Hôpital de la Croix-Rousse, GHN

Lyon, France, 69004

Actively Recruiting

2

Service d'Hématologie Clinique, Hôpital Lyon Sud

Lyon, France, 69310

Actively Recruiting

Loading map...

Research Team

T

Thibaud MATHIS, Dr

CONTACT

C

Christelle SZATANEK, MsC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here